{
  "schema_version": "3.1.1-production",
  "doc_id": "CT-19729",
  "evaluation_id": "CT-19729",
  "extraction_date": "2022-04-06",
  "extraction_metadata": {
    "processing_version": "auto",
    "parser": "auto",
    "annotateur_default": "auto",
    "niveau_confiance_default": 4,
    "source_files": {
      "F1": {
        "file_name": "ct_CT-19729_AMIRIOX_PIS_INS_AvisDef_CT19729.pdf",
        "type": "CT",
        "page_count": 5
      }
    }
  },
  "template_detecte": "CT_modern",
  "section_taxonomy_version": "1.0",
  "SegmentIndex": [
    {
      "segment_id": "CT-19729_seg_01",
      "section_label_normalise": "SYNTHESE_DE_L_AVIS",
      "section_label_brut": "L’essentiel",
      "template_detecte": "CT_modern",
      "page_start": 1,
      "page_end": 1,
      "char_start": null,
      "char_end": null,
      "heading_text": "L’essentiel",
      "expected_fields": [
        "smr_enum",
        "asmr_enum"
      ],
      "routing_hint": "Conclusion synthétique",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19729_seg_02",
      "section_label_normalise": "AMELIORATION_SMR",
      "section_label_brut": "Quel progrès ?",
      "template_detecte": "CT_modern",
      "page_start": 1,
      "page_end": 1,
      "char_start": null,
      "char_end": null,
      "heading_text": "Quel progrès ?",
      "expected_fields": [
        "asmr_enum"
      ],
      "routing_hint": "Évaluation ASMR",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19729_seg_03",
      "section_label_normalise": "INFORMATIONS_ADMINISTRATIVES",
      "section_label_brut": "CONTEXTE",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": null,
      "char_end": null,
      "heading_text": "01 CONTEXTE",
      "expected_fields": [
        "type_avis_enum",
        "produit_nom",
        "contexte_evaluation"
      ],
      "routing_hint": "Contexte de la demande",
      "label_confidence": 0.9
    },
    {
      "segment_id": "CT-19729_seg_04",
      "section_label_normalise": "INDICATIONS_THERAPEUTIQUES",
      "section_label_brut": "INDICATION",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": null,
      "char_end": null,
      "heading_text": "02 INDICATION",
      "expected_fields": [
        "indication"
      ],
      "routing_hint": "Indication thérapeutique",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19729_seg_05",
      "section_label_normalise": "COMPARATEURS_PERTINENTS",
      "section_label_brut": "COMPARATEURS CLINIQUEMENT PERTINENTS",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 3,
      "char_start": null,
      "char_end": null,
      "heading_text": "03 COMPARATEURS CLINIQUEMENT PERTINENTS",
      "expected_fields": [
        "comparateurs_HAS"
      ],
      "routing_hint": "Liste des comparateurs",
      "label_confidence": 0.9
    },
    {
      "segment_id": "CT-19729_seg_06",
      "section_label_normalise": "SERVICE_MEDICAL_RENDU",
      "section_label_brut": "CONCLUSIONS DE LA COMMISSION",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 4,
      "char_start": null,
      "char_end": null,
      "heading_text": "04 CONCLUSIONS DE LA COMMISSION",
      "expected_fields": [
        "smr_enum",
        "asmr_enum",
        "taux_remboursement"
      ],
      "routing_hint": "Conclusions SMR et ASMR",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19729_seg_07",
      "section_label_normalise": "PLACE_DANS_LA_STRATEGIE",
      "section_label_brut": "POPULATION CIBLE",
      "template_detecte": "CT_modern",
      "page_start": 4,
      "page_end": 4,
      "char_start": null,
      "char_end": null,
      "heading_text": "04.3 Population cible",
      "expected_fields": [
        "population_cible"
      ],
      "routing_hint": "Estimation population cible",
      "label_confidence": 0.9
    },
    {
      "segment_id": "CT-19729_seg_08",
      "section_label_normalise": "INFORMATIONS_ADMINISTRATIVES",
      "section_label_brut": "INFORMATIONS ADMINISTRATIVES ET REGLEMENTAIRES",
      "template_detecte": "CT_modern",
      "page_start": 5,
      "page_end": 5,
      "char_start": null,
      "char_end": null,
      "heading_text": "06 INFORMATIONS ADMINISTRATIVES ET REGLEMENTAIRES",
      "expected_fields": [
        "date_amm",
        "conditionnement",
        "code_atc"
      ],
      "routing_hint": "Informations réglementaires",
      "label_confidence": 0.9
    }
  ],
  "Identifiants_Produits_Liaison": [
    {
      "produit_id": "CT-19729_prod_AMIRIOX",
      "evaluation_id": "CT-19729",
      "nom_commercial": "AMIRIOX",
      "dci": "bimatoprost",
      "code_cip13": "34009 302 346 0 0",
      "titulaire_amm": "SIFI France",
      "code_atc": "S01EE03",
      "statut_prescription": "Liste I",
      "evidence": [
        {
          "field": "code_cip13",
          "f": "F1",
          "p": 5,
          "t": "34009 302 346 0 0",
          "m": "manual",
          "c": 1.0
        }
      ]
    },
    {
      "produit_id": "CT-19729_prod_LUMIGAN",
      "evaluation_id": "CT-19729",
      "nom_commercial": "LUMIGAN",
      "dci": "bimatoprost",
      "code_cip13": "Non renseigné",
      "titulaire_amm": "Allergan France S.A.S.",
      "code_atc": "S01EE03",
      "statut_prescription": "Non renseigné",
      "evidence": []
    }
  ],
  "Evaluations_HAS": [
    {
      "evaluation_id": "CT-19729",
      "Num_avis": "CT-19729",
      "produit_nom": "AMIRIOX 0,3 mg/ml, collyre en solution",
      "dci": "bimatoprost",
      "type_avis": "Inscription",
      "forme": "collyre en solution",
      "dosage": "0,3 mg/ml",
      "indication": "Réduction de la pression intraoculaire élevée chez les patients adultes atteints de glaucome chronique à angle ouvert ou d’hypertonie intraoculaire (en monothérapie ou en association aux bêtabloquants).",
      "classe_ATC": "S01EE03",
      "pathologie": "Glaucome chronique à angle ouvert, hypertonie intraoculaire",
      "maladie_rare": false,
      "ligne_traitement": "Traitement de première intention",
      "sous_groupe_population": "Adultes",
      "cim10_principal": "Non renseigné",
      "cim10_secondaires": [],
      "libelle_cim10": "Non renseigné",
      "source_cim10": "Non renseigné",
      "aire_therapeutique_niveau_1": "Ophthalmologie",
      "aire_therapeutique_niveau_2": "Glaucome",
      "aire_therapeutique_niveau_3": "Réduction pression intraoculaire",
      "source_aire_therapeutique": "Déduit ATC S01EE03",
      "design_etude": "Hybride sans conservateur",
      "niveau_preuve_brut": "Non renseigné",
      "niveau_preuve_interprete": "Non renseigné",
      "besoin_medical_brut": "Non renseigné",
      "besoin_medical_interprete": "Non renseigné",
      "pathologie_categorie_enum": "Autre",
      "age_restriction_flag": true,
      "age_restriction_detail": "Adultes",
      "biomarqueur_requis": "Aucun",
      "design_enum": "Non renseigné",
      "type_avis_enum": "Inscription",
      "gravite_patho": "Le glaucome et l’hypertonie oculaire sont des pathologies sévères pouvant entraîner la cécité.",
      "gravite_patho_enum": [
        "Grave"
      ],
      "type_population_cible": "Adultes",
      "pertinence_concurrence_therapeutique": "Comparateurs cliniquement pertinents identifiés : bêta-bloquants, analogues de prostaglandine avec et sans conservateur.",
      "caractere_innovant_reconnu": false,
      "perte_de_chance_citee": false,
      "historique_Has_produit": "Référence à l'avis de renouvellement de LUMIGAN du 20 mars 2019.",
      "historique_ASMR_comparateurs": "Non renseigné",
      "concurrence_therapeutique_recente": "Non renseigné",
      "vote_unanimite": null,
      "nb_votants": null,
      "nb_voix_pour": null,
      "nb_voix_contre": null,
      "nb_abstentions": null,
      "date_evaluation": "2022-04-06",
      "transcription_textuelle": "Non renseigné",
      "extraits_arguments": [],
      "evidence": [
        {
          "field": "produit_nom",
          "f": "F1",
          "p": 1,
          "t": "AMIRIOX 0,3 mg/ml, collyre en solution",
          "m": "manual",
          "c": 1.0
        },
        {
          "field": "indication",
          "f": "F1",
          "p": 2,
          "t": "Réduction de la pression intraoculaire élevée chez les patients adultes atteints de glaucome chronique à angle ouvert ou d’hypertonie intraoculaire (en monothérapie ou en association aux bêtabloquants).",
          "m": "manual",
          "c": 1.0
        },
        {
          "field": "classe_ATC",
          "f": "F1",
          "p": 5,
          "t": "S01EE03",
          "m": "manual",
          "c": 1.0
        },
        {
          "field": "date_evaluation",
          "f": "F1",
          "p": 1,
          "t": "6 AVRIL 2022",
          "m": "manual",
          "c": 1.0
        }
      ],
      "_meta": {}
    }
  ],
  "Essais_Cliniques": [],
  "Critères_Jugement": [],
  "Tolérance": {
    "tolerance_id": "CT-19729_tol",
    "evaluation_id": "CT-19729",
    "essai_id": null,
    "ae_total_pct": null,
    "ae_total_pct_comparateur": null,
    "sae_pct": null,
    "sae_pct_comparateur": null,
    "discontinuations_ae_pct": null,
    "discontinuations_ae_pct_comparateur": null,
    "deaths_ae_n": null,
    "deaths_ae_n_comparateur": null,
    "sae_data_available": false,
    "sae_superieur_comparateur": null,
    "deaths_reported": false,
    "EI_graves_detailles": [],
    "EI_frequents_detailles": [],
    "ei_grade_max": "Non renseigné",
    "deces_detailles": [],
    "signal_securite_flag": false,
    "signal_securite_detailles": [],
    "signal_ansm_flag": false,
    "EI_graves": "Les conservateurs présents dans les collyres peuvent induire, en cas d'administration chronique, des effets indésirables inflammatoires conjonctivaux et une toxicité de la surface oculaire.",
    "EI_frequents": "Non renseigné",
    "deces": "Non renseigné",
    "signal_securite": "Non renseigné",
    "evidence": [
      {
        "field": "EI_graves",
        "f": "F1",
        "p": 2,
        "t": "Les conservateurs présents dans les collyres peuvent induire, en cas d'administration chronique, des effets indésirables inflammatoires conjonctivaux et une toxicité de la surface oculaire.",
        "m": "manual",
        "c": 1.0
      }
    ],
    "_meta": {}
  },
  "Comparateurs_Essai": [],
  "Comparateurs_HAS": [
    {
      "comparateur_id": "CT-19729_compHAS_01",
      "evaluation_id": "CT-19729",
      "nom_comparateur_HAS": "LUMIGAN (bimatoprost) 0,3 mg/ml, collyre en solution",
      "type_comparateur": "Spécialité de référence",
      "comparateur_standard_soin": "Analogue de prostaglandine avec conservateur",
      "famille_comparateur": "Non renseigné",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 2,
          "t": "LUMIGAN (bimatoprost) 0,3 mg/ml, collyre en solution",
          "m": "manual",
          "c": 1.0
        }
      ],
      "_meta": {}
    },
    {
      "comparateur_id": "CT-19729_compHAS_02",
      "evaluation_id": "CT-19729",
      "nom_comparateur_HAS": "Bêta-bloquants avec conservateur (liste : BETOPTIC, CARTEOL, BETAGAN, OPHTIM, TIMABAK, TIMOCOMOD, TIMOPTOL)",
      "type_comparateur": "Traitement actif",
      "comparateur_standard_soin": "Médicament de première intention",
      "famille_comparateur": "Non renseigné",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 2,
          "t": "Bêta-bloquants avec conservateur",
          "m": "manual",
          "c": 1.0
        }
      ],
      "_meta": {}
    },
    {
      "comparateur_id": "CT-19729_compHAS_03",
      "evaluation_id": "CT-19729",
      "nom_comparateur_HAS": "Analogues de prostaglandine avec conservateur (liste : LUMIGAN, XALATAN, LATANOPROST NORIDERM, TRAVATAN)",
      "type_comparateur": "Traitement actif",
      "comparateur_standard_soin": "Médicament de première intention",
      "famille_comparateur": "Non renseigné",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 3,
          "t": "Analogues de prostaglandine avec conservateur",
          "m": "manual",
          "c": 1.0
        }
      ],
      "_meta": {}
    },
    {
      "comparateur_id": "CT-19729_compHAS_04",
      "evaluation_id": "CT-19729",
      "nom_comparateur_HAS": "Analogues de prostaglandine sans conservateur (liste : BIMATOPROST IDIFARMA, XIOP, LATAZED, SINETRAV, MONOPROST, VIZILATAN, VIZITRAV)",
      "type_comparateur": "Traitement actif",
      "comparateur_standard_soin": "Médicament de première intention",
      "famille_comparateur": "Non renseigné",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 3,
          "t": "Analogues de prostaglandine sans conservateur",
          "m": "manual",
          "c": 1.0
        }
      ],
      "_meta": {}
    }
  ],
  "Arguments_Decisionnels": [],
  "Données_Contexte": {
    "contexte_id": "CT-19729_ctx",
    "evaluation_id": "CT-19729",
    "ISP": "Non renseigné",
    "acces_precoce": "Aucun",
    "date_debut_acces_precoce": "Non renseigné",
    "date_fin_acces_precoce": "Non renseigné",
    "duree_acces_precoce_mois": null,
    "nombre_patients_acces_precoce": null,
    "conditions_arret_acces_precoce": "Non renseigné",
    "ISP_flag": false,
    "ISP_categorie": "Non renseigné",
    "type_acces_precoce_enum": "Aucun",
    "statut_reglementaire_ema": "AMM_standard",
    "date_AMM_ema": "2021-07-28",
    "date_avis_chmp": "Non renseigné",
    "innovation_therapeutique_ema": false,
    "designation_orpheline_ema": false,
    "prime_ema": false,
    "obligations_post_amm": [],
    "echeance_reexamen_amm": "Non renseigné",
    "nb_obligations_post_amm": null,
    "evaluation_internationale": "Non renseigné",
    "pays_evaluations": [],
    "decisions_internationales": [],
    "nb_decisions_internationales": null,
    "RDCR": "Non renseigné",
    "RDCR_num": null,
    "RDCR_intervalle": null,
    "RDCR_vs_seuil": "Non renseigné",
    "model_type": "Non renseigné",
    "perspective": "Non renseigné",
    "horizon_annees": null,
    "horizon_justification": "Non renseigné",
    "discount_rate_costs": null,
    "discount_rate_qalys": null,
    "DSA_flag": null,
    "PSA_flag": null,
    "scenario_analyses": [],
    "major_reserves": [],
    "nb_reserves_majeures": null,
    "impact_budgetaire_prevu": "Non renseigné",
    "impact_budgetaire_annee_1": null,
    "impact_budgetaire_annee_5": null,
    "impact_budgetaire_horizon": null,
    "hypothese_population_cible": null,
    "hypothese_penetration_marche_pct": null,
    "reserves_impact_budgetaire": [],
    "reserves_majeures": null,
    "population_cible_france": "environ 1 million de patients",
    "population_cible_nombre": 1000000,
    "population_cible_intervalle": null,
    "source_estimation_population": "Référence à avis SINETRAV du 24/03/2021",
    "incertitude_population": "Non renseigné",
    "population_cible_mediane": null,
    "suivi_post_inscription": false,
    "nature_suivi_post_inscription": "Non renseigné",
    "delai_suivi_mois": null,
    "delai_suivi_justification": "Non renseigné",
    "conditions_suivi": "Non renseigné",
    "echeance_suivi": "Non renseigné",
    "impact_si_non_realise": "Non renseigné",
    "delai_soumission_dossier": "Non renseigné",
    "delai_complement_demande": false,
    "dates_complement_demande": [],
    "delai_audition": false,
    "date_audition": "Non renseigné",
    "nb_total_reserves": null,
    "nb_total_reserves_mineures": null,
    "nb_totales_reserves_importantes": null,
    "nb_totales_reserves_majeures": null,
    "SMR_avant_audition_enum": "Non_renseigné",
    "SMR_apres_audition_enum": "Non_renseigné",
    "ASMR_avant_audition_enum": "Non_renseigné",
    "ASMR_après_audition_enum": "Non_renseigné",
    "type_critère_justification": "Non renseigné",
    "valeur_critère": "Non renseigné",
    "impact_décision": "Non renseigné",
    "estimation_mesure_impact": "Non renseigné",
    "contexte_evaluation": "Demande d'inscription d'un hybride sans conservateur de la spécialité de référence LUMIGAN. Pas d'essais cliniques nouveaux présentés, basé sur la bioéquivalence et le profil de sécurité sans conservateur.",
    "evidence": [
      {
        "field": "date_AMM_ema",
        "f": "F1",
        "p": 5,
        "t": "28 juillet 2021",
        "m": "manual",
        "c": 1.0
      },
      {
        "field": "population_cible_france",
        "f": "F1",
        "p": 4,
        "t": "environ 1 million de patients",
        "m": "manual",
        "c": 1.0
      }
    ],
    "_meta": {}
  },
  "Données_Textuelles": {
    "evaluation_id": "CT-19729",
    "texte_brut": "Non renseigné",
    "embedding": null
  },
  "SMR_ASMR_Par_Indication": [
    {
      "smr_asmr_id": "CT-19729_smrasmr_01",
      "evaluation_id": "CT-19729",
      "indication_precise": "Réduction de la pression intraoculaire élevée chez les patients adultes atteints de glaucome chronique à angle ouvert ou d’hypertonie intraoculaire (en monothérapie ou en association aux bêtabloquants).",
      "smr": "La Commission considère que le service médical rendu par AMIRIOX (bimatoprost) 0,3 mg/ml, collyre en solution est important dans l’indication de l’AMM.",
      "asmr": "Cette spécialité est un hybride qui n’apporte pas d’amélioration du service médical rendu (ASMR V) par rapport à la spécialité de référence LUMIGAN (bimatoprost) 0,3 mg/ml, collyre en solution.",
      "smr_revendique": "Non renseigné",
      "asmr_revendique": "Non renseigné",
      "justification_decisionnelle": "Avis favorable au remboursement. Taux de remboursement proposé : 65%. Pas de progrès par rapport à la spécialité de référence.",
      "population_cible_indication": "Adultes",
      "ligne_traitement_indication": "Première intention",
      "comparateurs_references_indication": "LUMIGAN (bimatoprost) 0,3 mg/ml, collyre en solution",
      "comparateur_id_HAS": "CT-19729_compHAS_01",
      "indication_structuree": {
        "ligne_traitement": "1L",
        "biomarqueur": "Aucun",
        "stade": "Non renseigné",
        "population_age": "Adultes"
      },
      "gain_survie_cite": false,
      "qol_cite": false,
      "tolerance_acceptable": true,
      "evidence_robustesse": "Non renseigné",
      "asmr_revendique_enum": "Non_renseigné",
      "evidence": [
        {
          "field": "smr",
          "f": "F1",
          "p": 3,
          "t": "La Commission considère que le service médical rendu par AMIRIOX (bimatoprost) 0,3 mg/ml, collyre en solution est important dans l’indication de l’AMM.",
          "m": "manual",
          "c": 1.0
        },
        {
          "field": "asmr",
          "f": "F1",
          "p": 4,
          "t": "Cette spécialité est un hybride qui n’apporte pas d’amélioration du service médical rendu (ASMR V) par rapport à la spécialité de référence LUMIGAN (bimatoprost) 0,3 mg/ml, collyre en solution.",
          "m": "manual",
          "c": 1.0
        }
      ],
      "_meta": {}
    }
  ],
  "Posologie_Par_Indication": [],
  "Timeline_Evenements": [
    {
      "event_id": "CT-19729_event_AMM_01",
      "evaluation_id": "CT-19729",
      "event_type": "AMM_EMA_DECISION",
      "event_date": "2021-07-28",
      "detail_brut": "Date initiale d'AMM (procédure décentralisée)",
      "source_doc": "F1",
      "detail_type_specifique": "Non renseigné",
      "acteurs_impliques": [],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "delai_amm_ct_jours": 251,
      "delai_ct_jo_jours": null,
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 5,
          "t": "28 juillet 2021",
          "m": "manual",
          "c": 1.0
        }
      ],
      "_meta": {}
    },
    {
      "event_id": "CT-19729_event_CT_01",
      "evaluation_id": "CT-19729",
      "event_type": "ADOPTION_CT",
      "event_date": "2022-04-06",
      "detail_brut": "Date d'examen et d'adoption de l'avis",
      "source_doc": "F1",
      "detail_type_specifique": "Non renseigné",
      "acteurs_impliques": [],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "delai_amm_ct_jours": null,
      "delai_ct_jo_jours": null,
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 5,
          "t": "06/04/2022",
          "m": "manual",
          "c": 1.0
        }
      ],
      "_meta": {}
    }
  ],
  "Timeline_Delais": {
    "evaluation_id": "CT-19729",
    "delai_amm_ct_jours": 251,
    "delai_transcription_ct_jours": null,
    "delai_audition_ct_jours": null,
    "complement_demande_mentionne": false,
    "audition_realisee": false,
    "evidence": [],
    "_meta": {}
  },
  "Features_Modele": {
    "evaluation_id": "CT-19729",
    "is_orphan": false,
    "classe_ATC_l2": "S01",
    "aire_therapeutique": "Ophthalmologie",
    "type_avis_enum": "Inscription",
    "innovation_reconnue": false,
    "perte_de_chance_citee": false,
    "ligne_traitement_num": 1,
    "is_rct": false,
    "n_essais": 0,
    "n_rct": 0,
    "presence_qol": false,
    "effet_principal_magnitude_num": null,
    "critere_principal_dur": false,
    "suivi_median_mois_max": null,
    "sae_pct_num": null,
    "discontinuations_pct_num": null,
    "critere_principal_description": "Non renseigné",
    "p_value_log10": null,
    "ceesp_present": false,
    "rdcr_num": null,
    "rdcr_log": null,
    "impact_budget_cat": "Non renseigné",
    "reserves_majeures": false,
    "nb_reserves_majeures": null,
    "vote_unanimite": null,
    "nb_votants": null,
    "voix_pour_pct": null,
    "association_patient_intervenue": false,
    "comparateur_placebo": false,
    "comparateur_soc": true,
    "nb_clockstops": 0,
    "annee_ct": 2022,
    "trimestre_ct": 2,
    "template_ere": "CT_modern",
    "missingness_indicators": null,
    "_meta": {}
  },
  "Relations": [],
  "Annotation_View": []
}